Evidence Grade A — Regulatory approved. 461 published studies. 17 registered clinical trials.
Medically reviewed by a licensed medical professional
Loading...
Telavancin (sold as Vibativ) is an intravenous antibiotic derived from vancomycin with enhanced potency, approved for complicated skin infections and hospital-acquired pneumonia caused by gram-positive bacteria including MRSA. It combines two killing mechanisms — blocking cell wall construction and disrupting the bacterial membrane — for faster bacterial killing than vancomycin alone.
Telavancin is also known by these brand and alternate names:
461 published studies: 326 human, 29 animal, 138 in-vitro, 162 reviews
Telavancin is marketed as Vibativ (approved September 2009 for skin infections; June 2013 for hospital-acquired pneumonia). It is administered as a once-daily intravenous infusion.
In skin infection trials, telavancin was non-inferior to vancomycin. In hospital-acquired pneumonia, it showed a trend toward superiority in the S. aureus subgroup. However, telavancin carries a boxed warning regarding foetal risk and a risk of kidney toxicity — patients with pre-existing kidney disease (creatinine clearance below 50 mL/min) had increased mortality in clinical trials. These safety concerns, combined with the availability of other options, have limited its clinical uptake compared to daptomycin and the longer-acting lipoglycopeptides.
Telavancin combines two killing mechanisms. Like vancomycin, it blocks cell wall construction by binding to D-Ala-D-Ala, but approximately 14 times more potently. Uniquely, its lipophilic side chain also inserts into the bacterial membrane, causing rapid depolarisation — the membrane loses its electrical charge, which is essential for the bacterium's energy production and nutrient transport. This dual attack (cell wall plus membrane) produces faster bacterial killing than vancomycin alone.
Phase III trials involving approximately 3,300 patients showed telavancin was non-inferior to vancomycin for skin infections and showed a trend toward superiority in pneumonia caused by S. aureus. However, a three-component boxed warning has significantly limited its use: increased mortality in patients with pre-existing kidney disease, direct kidney toxicity, and risk of harm to unborn babies. These safety concerns, combined with the availability of other effective options (daptomycin, dalbavancin, oritavancin), have relegated telavancin to a niche role — typically reserved for gram-positive infections where other options have failed or are not suitable. It also interferes with coagulation blood tests and causes a distinctive metallic or soapy taste. No paediatric data are available.
PeptideTrace tracks 17 registered clinical trials for Telavancin sourced from ClinicalTrials.gov.
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
Telavancin Pharmacokinetics in Cystic Fibrosis Patients
Pharmacokinetics of Telavancin in Normal and Obese Subjects
Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5
Telavancin Pediatric PK Study (Ages >12 Months to 17 Years)
FDA ORIG 1
FDA SUPPL 2
EMA Marketing Authorisation
FDA SUPPL 4
FDA SUPPL 6
FDA SUPPL 3
FDA SUPPL 8
FDA SUPPL 7
FDA SUPPL 9
FDA SUPPL 10
FDA SUPPL 11
FDA SUPPL 13
FDA SUPPL 12
FDA SUPPL 14
FDA SUPPL 15
FDA SUPPL 16
Telavancin is a semisynthetic lipoglycopeptide from vancomycin, heptapeptide core, MW 1,755.6 Da. Decylaminoethyl side chain (membrane interaction) and (phosphonomethyl)aminomethyl group at AA7 (renal excretion). ~14-fold greater potency than vancomycin. IV 10 mg/kg once daily over 60 min. Half-life 7-9 hours. Protein binding ~90-93%.
Dual mechanism. First: binds D-Ala-D-Ala termini blocking transglycosylation and transpeptidation - ~14-fold more potent than vancomycin (IC50 0.14 vs. 2.0 microM in MRSA). Second: decylaminoethyl moiety interacts with bacterial lipid bilayer causing rapid membrane depolarization and permeability increase, leaking ATP and K+. Produces concentration-dependent bactericidal activity.
Marketed as Vibativ. Approved September 11, 2009 (cSSSI) and June 21, 2013 (HABP/VABP). ATLAS 1&2 (cSSSI; N=1,794): 88.3% vs. 87.1%. ATTAIN 1&2 (HABP/VABP; N=1,503): 58.9% vs. 59.5%; S. aureus subgroup superior 84.2% vs. 74.3% (P=0.035). Increased mortality with CrCl <=50 mL/min. Indications: cSSSI; HABP/VABP caused by S. aureus when alternatives unsuitable.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
Zilucoplan is marketed as Zilbrysq (approved October 2023) for anti-acetylcholine receptor antibody-positive generalised myasthenia gravis in adults. Administered as a daily subcutaneous self-injection. In the RAISE trial, zilucoplan showed statistically significant improvements in both activities of daily living and quantitative muscle strength scores compared to placebo, with improvements evident from week one. Its key differentiator from existing complement inhibitors (eculizumab, ravulizumab) is the self-injectable format — those alternatives require hospital-based intravenous infusions. As with all complement inhibitors, patients require meningococcal vaccination before starting treatment due to increased susceptibility to meningococcal infection.
Daptomycin is marketed as Cubicin (approved September 2003). It is indicated for complicated skin and soft tissue infections and S. aureus bloodstream infections including right-sided endocarditis. Administered as a once-daily intravenous infusion. A key limitation is that daptomycin cannot be used for pneumonia — lung surfactant inactivates the drug. In the bacteraemia trial, daptomycin was non-inferior to vancomycin with significantly lower rates of kidney problems (11% versus 26%). Creatine kinase (CK) levels must be monitored during treatment, as daptomycin can cause muscle toxicity. Generics became available after patent expiry, significantly reducing cost.
Evidence Reviews
Timelines
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
